A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer
- Author
- BECOUARN, Y1 ; SENESSE, P2 ; THEZENAS, S2 ; BOUCHER, E3 ; ADENIS, A4 ; CANY, L5 ; JACOB, J. H6 ; CVITKOVIC, F7 ; MONTOTO-GRILLOT, C8 ; YCHOU, M2
[1] Department of Digestive Oncology, Institut Bergonié, Regional Cancer Center, Bordeaux, France
[2] Centre Régional de Lutte contre le Cancer Val d'Aurelle-Paul Lamarque, Montpellier, France
[3] Centre Eugène Marquis, Rennes, France
[4] Centre Oscar Lambret, Lille, France
[5] Clinique Francheville, Périgueux, France
[6] Centre François Baclesse, Caen, France
[7] Centre René Huguenin, Saint-Cloud, France
[8] Fédération Nationale des Centres de Lutte Contre le Cancer, Paris, France - Source
Annals of oncology. 2007, Vol 18, Num 12, pp 2000-2005, 6 p ; ref : 27 ref
- ISSN
- 0923-7534
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- FU advanced colorectal cancer first-line treatment irinotecan oxaliplatin
- Keyword (fr)
- Anticancéreux Appareil digestif Bras Cancer colorectal Chimiothérapie Efficacité traitement Essai clinique phase II Essai clinique Homme Irinotécan Métastase Norme Oxaliplatine Protocole thérapeutique Randomisation Stade avancé Toxicité Traitement de première intention Traitement induction Tumeur maligne Agent alkylant Camptothécine dérivé Cancer DNA topoisomerase Enzyme Inhibiteur de la topoisomérase I Inhibiteur enzyme Isomerases Pathologie de l'appareil digestif Pathologie de l'intestin Pathologie du côlon Pathologie du rectum Platine II Complexe Traitement
- Keyword (en)
- Antineoplastic agent Digestive system Arm Colorectal cancer Chemotherapy Treatment efficiency Phase II trial Clinical trial Human Irinotecan Metastasis Standards Oxaliplatin Therapeutic protocol Randomization Advanced stage Toxicity First line treatment Induction treatment Malignant tumor Alkylating agent Camptothecin derivatives Cancer DNA topoisomerase Enzyme Topoisomerase I inhibitor Enzyme inhibitor Isomerases Digestive diseases Intestinal disease Colonic disease Rectal disease Platinum II Complexes Treatment
- Keyword (es)
- Anticanceroso Aparato digestivo Brazo Cancer de colon y recto Quimioterapia Eficacia tratamiento Ensayo clínico fase II Ensayo clínico Hombre Irinotecán Metástasis Norma Oxaliplatino Protocolo terapéutico Aleatorización Estadio avanzado Toxicidad Tratamiento de primera línea Tratamiento inductivo Tumor maligno Agente alquilante Camptothecin derivado Cáncer DNA topoisomerase Enzima Inhibidor topoisomerase I Inhibidor enzima Isomerases Aparato digestivo patología Intestino patología Colón patología Recto patología Platino II Complejo Tratamiento
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13B Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / 002B13B01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 19972652
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/annonc/mdm379 
https://dx.doi.org/10.1093/annonc/mdm379
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm379\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:347:\"A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"2000\";s:8:\"\u0000*\u0000epage\";s:4:\"2005\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BECOUARN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"Y\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"SENESSE, P\";i:1;s:11:\"THEZENAS, S\";i:2;s:10:\"BOUCHER, E\";i:3;s:9:\"ADENIS, A\";i:4;s:7:\"CANY, L\";i:5;s:11:\"JACOB, J. H\";i:6;s:12:\"CVITKOVIC, F\";i:7;s:18:\"MONTOTO-GRILLOT, C\";i:8;s:8:\"YCHOU, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:347:\"A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm379\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:347:\"A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"2000\";s:8:\"\u0000*\u0000epage\";s:4:\"2005\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BECOUARN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"Y\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"SENESSE, P\";i:1;s:11:\"THEZENAS, S\";i:2;s:10:\"BOUCHER, E\";i:3;s:9:\"ADENIS, A\";i:4;s:7:\"CANY, L\";i:5;s:11:\"JACOB, J. H\";i:6;s:12:\"CVITKOVIC, F\";i:7;s:18:\"MONTOTO-GRILLOT, C\";i:8;s:8:\"YCHOU, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:347:\"A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm379\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm379\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:347:\"A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"2000\";s:8:\"\u0000*\u0000epage\";s:4:\"2005\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BECOUARN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"Y\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"SENESSE, P\";i:1;s:11:\"THEZENAS, S\";i:2;s:10:\"BOUCHER, E\";i:3;s:9:\"ADENIS, A\";i:4;s:7:\"CANY, L\";i:5;s:11:\"JACOB, J. H\";i:6;s:12:\"CVITKOVIC, F\";i:7;s:18:\"MONTOTO-GRILLOT, C\";i:8;s:8:\"YCHOU, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:347:\"A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm379\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:347:\"A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"2000\";s:8:\"\u0000*\u0000epage\";s:4:\"2005\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BECOUARN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"Y\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"SENESSE, P\";i:1;s:11:\"THEZENAS, S\";i:2;s:10:\"BOUCHER, E\";i:3;s:9:\"ADENIS, A\";i:4;s:7:\"CANY, L\";i:5;s:11:\"JACOB, J. H\";i:6;s:12:\"CVITKOVIC, F\";i:7;s:18:\"MONTOTO-GRILLOT, C\";i:8;s:8:\"YCHOU, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:347:\"A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdm379\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:347:\"A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"12\";s:8:\"\u0000*\u0000spage\";s:4:\"2000\";s:8:\"\u0000*\u0000epage\";s:4:\"2005\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BECOUARN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"Y\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"SENESSE, P\";i:1;s:11:\"THEZENAS, S\";i:2;s:10:\"BOUCHER, E\";i:3;s:9:\"ADENIS, A\";i:4;s:7:\"CANY, L\";i:5;s:11:\"JACOB, J. H\";i:6;s:12:\"CVITKOVIC, F\";i:7;s:18:\"MONTOTO-GRILLOT, C\";i:8;s:8:\"YCHOU, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:347:\"A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
